Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper versions made by compounding pharmacies.
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
Related: Teladoc, LifeMD partner with Eli Lilly on GLP-1s
Patients can now get a Zepbound prescription through Hims’ telehealth platform, a spokesperson said in an email. A monthly prescription for Zepbound will cost $1,899 a month, according to the company’s website. This is roughly $800 more than the list price Eli Lilly & Co. charges for its drug, and includes a Hims membership, unlimited consultations with a provider and treatment support, the spokesperson said.
Hims also said it will begin selling a generic version Novo Nordisk A/S’s Saxenda, a weight-loss shot that is taken daily.
© 2025 Bloomberg L.P.
